{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:18:00Z","timestamp":1773785880250,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>Co\u2010administration of hepatitis C virus (HCV) direct\u2010acting antivirals (DAAs) with anti\u2010epileptics or mood stabilizers with cytochrome P450 (CYP) and\/or drug transport\u2010inducing properties is contraindicated due to concerns of subtherapeutic DAA levels that can lead to treatment failure and viral resistance. The recommended strategy is to change the interacting medication to a different agent that does not have inducing properties, but this is not always possible depending on the clinical scenario. We report on three patients who received DAAs for their HCV infection while remaining on the contraindicated anti\u2010epileptic or mood stabilizer by utilizing CYP and drug transport inhibitors as pharmacokinetic enhancers to attempt to overcome the induction effects and maximize chances of achieving sustained virologic response (SVR). All patients achieved SVR despite the drug\u2013drug interactions and there were no safety concerns. In patients facing this unique clinical quandary, the use of CYP and drug transport inhibitors appears to be a safe and possible strategy.<\/jats:p>","DOI":"10.1111\/bcp.15712","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T05:15:00Z","timestamp":1678684500000},"page":"1891-1895","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment of hepatitis C virus infection in patients on anti\u2010epileptics or mood stabilizers using pharmacokinetic enhancers"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5125-8031","authenticated-orcid":false,"given":"Jeffrey","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Pharmacy UC San Diego Health  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Pharmacy UC San Diego Health  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlina","family":"Mansour","sequence":"additional","affiliation":[{"name":"Department of Pharmacy UC San Diego Health  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Summer","family":"Collier","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine UC San Diego Health  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranab","family":"Barman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine UC San Diego Health  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019. Accountability for the global health sector strategies, 2016\u20132021","author":"World Health Organization","year":"2019"},{"key":"e_1_2_9_3_1","unstructured":"Epclusa [package insert]: Gilead; 2022.https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/liver-disease\/epclusa\/epclusa_pi.pdf. Accessed March 20 2023."},{"key":"e_1_2_9_4_1","unstructured":"Mavyret [package insert]. Abbvie; 2021.https:\/\/www.rxabbvie.com\/pdf\/mavyret_pi.pdf. Accessed March 20 2023."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002331"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201018552\u20107"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021270"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.010"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190020977762"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.040"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2012.03671.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010173200"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1072"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2605"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpsmen.2014.10.006"},{"key":"e_1_2_9_16_1","unstructured":"Tybost [package insert]: Gilead;2017.https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/tybost\/tybost_pi.pdf. Accessed March 20 2023."},{"key":"e_1_2_9_17_1","unstructured":"Nizoral [package insert]: Janssen;2014.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/018533s041lbl.pdf"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.28.1805"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.067744"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002857"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx459"},{"key":"e_1_2_9_22_1","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Kosloski MP","year":"2017"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz439"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.07.002"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2007.00924.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.1984.tb02482.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15712","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T17:36:54Z","timestamp":1692639414000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/bcp.15712"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15712","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]}}}